Shire Collaboration Brings Validation To ArmaGen’s Drug-Delivery Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
While awaiting finalization of its merger with AbbVie, Shire signed a deal with privately held ArmaGen to license technology that could enable Elaprase to be delivered across the blood-brain barrier. That would enable the Hunter syndrome therapy to treat CNS manifestations of the disease as well as systemic symptoms.
You may also be interested in...
Emerging Markets Earnings Roundup: AbbVie (Part 5)
AbbVie was required to stay largely mum on its second quarter earnings call as it complies with the UK Takeover Code in its deal with Shire. But some numbers on Humira were released for international sales that show the franchise growing well outside of the U.S.
More Than Window Dressing: Ornskov Seen As Key Asset In AbbVie’s Buyout Of Shire
The Shire CEO will oversee integration of his company into AbbVie and head a focused rare-disease unit in the new company, but longer-term might be in position to succeed AbbVie CEO Gonzalez. AbbVie may look to Sanofi’s acquisition of Genzyme for a template on how to merge a rare diseases specialty play into big pharma.
Shire’s Elaprase For Hunter Syndrome To Undergo Long-Term Outcomes Study
Shire will do long-term follow up for its newly approved Hunter syndrome therapy Elaprase through a 15-year outcomes survey